(Q51076251)

28 March 2018

title

The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes. (English)

1 reference

28 March 2018

0 references

1

1 reference

28 March 2018

author name string

Robert G Brodows

series ordinal

2

1 reference

28 March 2018

David D'Alessio

series ordinal

3

1 reference

28 March 2018

publication date

11 April 2013

1 reference

28 March 2018

published in

Clinical Endocrinology

1 reference

28 March 2018

volume

80

1 reference

28 March 2018

issue

4

1 reference

28 March 2018

page(s)

545-553

1 reference

28 March 2018

The biology of incretin hormones

cites work

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

21 January 2018

1 reference

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance

21 January 2018

1 reference

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

21 January 2018

1 reference

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

21 January 2018

1 reference

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.

21 January 2018

1 reference

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea

21 January 2018

1 reference

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

A model-based method for assessing insulin sensitivity from the oral glucose tolerance test

21 January 2018

1 reference

Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test.

21 January 2018

1 reference

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

21 January 2018

1 reference

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis

21 January 2018

1 reference

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

21 January 2018

1 reference

Quantitative study of insulin secretion and clearance in normal and obese subjects

21 January 2018

1 reference

The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

The stunned beta cell: a brief history

21 January 2018

1 reference

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

21 January 2018

1 reference

Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake

21 January 2018

1 reference

Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/CEN.12199

1 reference

28 March 2018

1 reference

28 March 2018